Company intelligence / Profile preview

Jiangsu Walvax Biotech

Kunming, Yunnan, China

Ownership: Private
Employees: ~1000
Development stage: Other

Overview

Walvax has multiple approved vaccines including ARCoV (SARS-CoV-2 mRNA Vaccine approved in China and Indonesia), 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine, Recombinant HPV Bivalent Vaccine, and others; ongoing Phase 3 and BLA for 9-valent HPV and PCV20.[1][3][4][10]

Therapeutic areas: OncologyInfectious Diseases
Modalities: Prophylactic vaccinePolysaccharide vaccinemRNA vaccineConjugated vaccineMultivalent vaccineRecombinant protein vaccine
Industry: Biotech

Partnerships

GSK (Joint Venture for paediatric vaccines including MMR/Priorix)Bill & Melinda Gates Foundation (grants for HPV vaccines)CEPI (COVID-19 vaccines)Abogenbio (COVID-19 mRNA vaccine)

Beyond the preview

Go deeper on Jiangsu Walvax Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jiangsu Walvax Biotech.

Explore the full profile